Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.

Saved in:
Bibliographic Details
Title: Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Authors: Layman RM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: rlayman@mdanderson.org., Han HS; Moffit Cancer Center, Tampa, FL, USA., Rugo HS; Division of Hematology and Oncology, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Stringer-Reasor EM; Division of Hematology Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA., Specht JM; Division of Hematology and Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WA, USA., Dees EC; Division of Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Kabos P; Division of Medical Oncology, University of Colorado Hospital, Aurora, CO, USA., Suzuki S; Celcuity, Minneapolis, MN, USA., Mutka SC; Celcuity, Minneapolis, MN, USA., Sullivan BF; Celcuity, Minneapolis, MN, USA., Gorbatchevsky I; Celcuity, Minneapolis, MN, USA., Wesolowski R; Department. of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Source: The Lancet. Oncology [Lancet Oncol] 2024 Apr; Vol. 25 (4), pp. 474-487.
Publication Type: Multicenter Study; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(24)00034-2